Real-Time Technology Adoption: Assessing Early Real-World Trends in Renal Denervation Therapy Following Initial Device Approval
Author(s)
Michelle Sweeny, MSc1, Maria Castro, B.S.2, Joe McGonigle, PhD3, Frank P Hurst, MD4, Michelle Edwards, MBA5, Christina Mack, MSPH, PhD4.
1IQVIA, Toronto, ON, Canada, 2IQVIA, Vancouver, ON, Canada, 3IQVIA, Eagan, MN, USA, 4IQVIA, Durham, NC, USA, 5Bridgewater, NJ, USA.
1IQVIA, Toronto, ON, Canada, 2IQVIA, Vancouver, ON, Canada, 3IQVIA, Eagan, MN, USA, 4IQVIA, Durham, NC, USA, 5Bridgewater, NJ, USA.
Presentation Documents
OBJECTIVES: Over 10 million adults in the US live with treatment-resistant hypertension. Renal denervation therapy, approved in November 2023, offers a low-risk treatment option. This US-based Real World Evidence (RWE) study aims to characterize early trends in renal denervation therapy.
METHODS: We analyzed patient claims using open-source longitudinal medical and prescription claims datasets from 2022-2024. Patients with a renal denervation procedure code between April 2022 - September 2024 were included. In total, 161 patients treated by 78 HCPs were analyzed.
RESULTS: Renal denervation patients had an average age of 62.5 years (21-84 years), compared with hypertension patients at 64.6 years (0-85 years). 65% of patients submitted claims through Third Party Commercial payers, 31% to Medicare, 1% to Medicaid, and 4% to Medicare Advantage. Hypertension was the primary diagnosis on 74% of renal denervation claims, followed by atrial fibrillation (9%), atherosclerosis (5%), and other diagnoses (12%). 80% of procedures were done in outpatient hospital settings, 15% in inpatient hospital settings, 3% in ambulatory surgical centers, and 2% in physician offices/office-based labs. The 78 HCPs treating these patients were mainly cardiologists (76%) and electrophysiologists (12%). 35% of patients were referred by another cardiologist, and 26% by a primary care physician. Patients (n=89) with sufficient prescription data history were analyzed for post-procedure drug use trends. Overall, 51% of patients experienced a decrease in medication usage, 36% saw an increase, and 13% had no change. The average number of hypertension products per patient decreased from 2.9 pre-procedure to 2.7 post-procedure.
CONCLUSIONS: Our study shows that patients treated with Renal Denervation therapy were slightly younger than average, commercially insured, and most likely to be treated in an outpatient setting by a cardiologist. The majority exhibit a reduction in medication usage within the pre- and post-90-day timeframes, though continued use of these medications is still observed.
METHODS: We analyzed patient claims using open-source longitudinal medical and prescription claims datasets from 2022-2024. Patients with a renal denervation procedure code between April 2022 - September 2024 were included. In total, 161 patients treated by 78 HCPs were analyzed.
RESULTS: Renal denervation patients had an average age of 62.5 years (21-84 years), compared with hypertension patients at 64.6 years (0-85 years). 65% of patients submitted claims through Third Party Commercial payers, 31% to Medicare, 1% to Medicaid, and 4% to Medicare Advantage. Hypertension was the primary diagnosis on 74% of renal denervation claims, followed by atrial fibrillation (9%), atherosclerosis (5%), and other diagnoses (12%). 80% of procedures were done in outpatient hospital settings, 15% in inpatient hospital settings, 3% in ambulatory surgical centers, and 2% in physician offices/office-based labs. The 78 HCPs treating these patients were mainly cardiologists (76%) and electrophysiologists (12%). 35% of patients were referred by another cardiologist, and 26% by a primary care physician. Patients (n=89) with sufficient prescription data history were analyzed for post-procedure drug use trends. Overall, 51% of patients experienced a decrease in medication usage, 36% saw an increase, and 13% had no change. The average number of hypertension products per patient decreased from 2.9 pre-procedure to 2.7 post-procedure.
CONCLUSIONS: Our study shows that patients treated with Renal Denervation therapy were slightly younger than average, commercially insured, and most likely to be treated in an outpatient setting by a cardiologist. The majority exhibit a reduction in medication usage within the pre- and post-90-day timeframes, though continued use of these medications is still observed.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
MT5
Topic
Medical Technologies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)